Amgen's stock price has increased by 13% due to the promising outlook of its new obesity drug, MariTide. The drug's unique dual mechanism and less frequent dosing are seen as competitive advantages, potentially leading to significant market share and $5 billion in peak annual revenue. This development is crucial for Amgen's growth, especially in the competitive landscape against companies like Eli Lilly and Novo Nordisk.